Potassium acetate


Concise Prescribing Info
Indications/Uses
Treatment and prohylaxis of hypokalaemia.
Dosage/Direction for Use
Adult : IV Normal daily requirements: 40-80 mEq/24 hour. Dose and rate of administration are dependent upon the ECG and serum K levels. Max infusion rate: 1 mEq/kg/hour.
Dosage Details
Intravenous
Hypokalaemia
Adult: For treatment and prophylaxis: Normal daily requirements: 40-80 mEq/24 hour, given via infusion at a max rate of 1 mEq/kg/hour. Dose and rate of administration are dependent upon the ECG and serum K levels.
Child: For treatment and prophylaxis: Normal daily requirements: 2-3 mEq/kg/24 hour; Newborn: 2-6 mEq/kg/24 hour. Dose and rate of administration are dependent upon the ECG and serum K levels. Max infusion rate: 1 mEq/kg/hour.
Reconstitution
Potassium acetate should be diluted to a final concentration approx 10-40 mEq/100 mL with dextrose 5 or 10% inj or dextrose 5% in lactated Ringer’s, NaCl 0.9%, lactated Ringer’s, Hartmann’s solution.
Contraindications
Hyperkalaemia and associated diseases. Adrenal insufficiency. Severe renal impairment.
Special Precautions
Patient with acid-base alterations, metabolic or respiratory alkalosis, dehydration, hyperkalaemia, K-altering conditions (e.g. heat cramps, severe tissue breakdown from trauma or burns), cardiac disease (e.g. cardiac arrhythmias, heart block, CHF). Severe hepatic and mild to moderate renal impairment. Pregnancy and lactation.
Adverse Reactions
Significant: Hyperkalaemia, alkalosis.
Injury, poisoning and procedural complications: Inj site pain, phlebitis, extravasation.
Potentially Fatal: Severe hyperkalaemia.
IV/Parenteral: C
MonitoringParameters
Monitor serum electrolytes including K, bicarbonate and Mg levels; ECG, and acid-base status. Assess adequate replacement, repeat serum K test 2-4 hr after admin. Monitor infusion site reactions (e.g. extravasation).
Overdosage
Symptoms: Fatal hyperkalaemia, manifested by increased serum K concentration and ECG changes and may lead to cardiac depression, arrhythmias or arrest. Management: Discontinue K acetate; agents and food containing K or which increases serum K levels. Correct acidosis with Na bicarbonate infusion. Manage cardiac toxicity with Ca gluconate. Continuously monitor ECG. In severe cases, haemodialysis, or peritoneal dialysis, or exchange resin treatment may be necessary.
Drug Interactions
May increase hyperkalaemic effect of K sparing diuretics (e.g. amiloride), ACE inhibitors (e.g. captopril), K-containing salts.
Potentially Fatal: May increase risk of cardiotoxicity with digoxin.
Action
Description: Potassium acetate acts as an electrolyte replenisher of K ions. K, the major cation of the intracellular fluid, is essential for maintenance of acid-base and fluid and electrolyte balance of the cell. It also plays a vital role in the conduction of nerve impulses, contraction of cardiac, smooth and skeletal muscles, gastric secretion, normal renal function and carbohydrate metabolism.
Pharmacokinetics:
Distribution: Distributed to cells via active transport from extracellular fluid. Enters breast milk.
Excretion: Mainly via urine; faeces and sweat (small amount).
Chemical Structure

Chemical Structure Image
Potassium acetate

Source: National Center for Biotechnology Information. PubChem Database. Potassium acetate, CID=517044, https://pubchem.ncbi.nlm.nih.gov/compound/Potassium-acetate (accessed on Jan. 23, 2020)

Storage
Store between 20-25°C.
MIMS Class
ATC Classification
B05XA17 - potassium acetate ; Belongs to the class of electrolyte solutions used in I.V. solutions.
References
Anon. Potassium Acetate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/01/2018.

Buckingham R (ed). Potassium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/01/2018.

Potassium Acetate Injection, Solution, Concentrate (Hospira, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/01/2018.

Disclaimer: This information is independently developed by MIMS based on Potassium acetate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in